Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CytomX Therapeutics Inc CTMX

Healthcare Biotechnology
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic... see more

Recent & Breaking News (NDAQ:CTMX)

CytomX to Present at the Cantor Fitzgerald Healthcare Conference

GlobeNewswire September 13, 2017

CytomX Announces Upcoming Trials in Progress Poster Presentations at European Society for Medical Oncology Annual Meeting

GlobeNewswire September 8, 2017

CytomX Announces Second Quarter 2017 Financial Results and Mid-Year Update Webcast Conference Call

GlobeNewswire August 7, 2017

Investor Network: CytomX Therapeutics, Inc. to Host Earnings Call

Accesswire August 7, 2017

CytomX Therapeutics to Announce Second Quarter 2017 Financial Results and Provide Mid-Year Update

GlobeNewswire July 27, 2017

CytomX Achieves Development Milestone in Strategic Oncology Collaboration with AbbVie for CD71-Targeting Probody Drug Conjugate  

GlobeNewswire June 29, 2017

CytomX Announces the First Patient Treated in Phase 1/2 PROCLAIM-CX-2009 Trial

GlobeNewswire June 28, 2017

CytomX to Present at the Jefferies 2017 Global Healthcare Conference

GlobeNewswire May 25, 2017

CytomX Announces Upcoming Poster Presentation at American Society for Clinical Oncology Annual Meeting

GlobeNewswire May 17, 2017

CytomX Announces Management Team Changes

GlobeNewswire May 15, 2017

CytomX Announces First Quarter 2017 Financial Results

GlobeNewswire May 5, 2017

CytomX Therapeutics to Announce First Quarter 2017 Financial Results

GlobeNewswire April 27, 2017

CytomX Therapeutics Appoints Marion McCourt to Board of Directors

GlobeNewswire March 30, 2017

Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide

Benzinga.com  March 20, 2017

12 Biggest Mid-Day Gainers For Monday

Benzinga.com  March 20, 2017

CytomX Therapeutics Announces Teleconference and Webcast to Provide Corporate Update

GlobeNewswire March 19, 2017

CytomX Announces Full-Year 2016 Financial Results

GlobeNewswire March 2, 2017

CytomX Therapeutics to Announce Full-Year 2016 Financial Results

GlobeNewswire March 1, 2017

CytomX Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire February 21, 2017

CytomX to Present at Upcoming Investor Conferences

GlobeNewswire February 2, 2017